Shaare Zedek Study: 94% Of COVID-19 Patients Have Symptoms 3 Months After Recovery

By Staff Reporter
Posted on 02/23/21 | News Source: Arutz-7

New study by Jerusalem’s Shaare Zedek Medical Center shows encouraging long-term recovery data for COVID-19 patients.

With continued attention on the long-term effects of the coronavirus, research conducted at Jerusalem’s Shaare Zedek Medical Center indicates that 95 percent of recovered COVID-19 patients showed no evidence of irreversible respiratory or cardiac damage after a period of three months and that the majority of symptoms had dissipated by six months.

Professor Gabriel Izbicki, Director of the Pulmonary Institute at Shaare Zedek who was responsible for the study said, “We can cautiously report that based on our study, the majority of symptoms passed within a period of three to six months.”

Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more

Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens

The study was based on data gathered from 166 patients between the ages of 19 and 86 who had recovered from coronavirus. The study did find that at the three month mark, 94 percent of patients were still reporting symptoms with the most prominent - shortness of breath - being found in 57 percent of the patients.

Professor Izbicki noted that the results were certainly encouraging, “Almost all the patients we studied after six months reported a marked improvement in their overall conditions and the test results reflected that. We found that regular fitness activities of three to four times a week were direct contributors to helping the patient recover that much more quickly.”

The data showed that at three months after recovery the most prevalent lasting symptoms were shortness of breath found in 65 percent of the more serious cases and 50 percent of more moderate cases. Fifty-five percent of patients reported overall weakness, 25 percent a sustained cough, 18 percent chest pain, 11 percent loss of taste and smell and 8 percent exhibiting neurological symptoms like dizziness or weakness in the limbs. Read more at Arutz-7